Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Gastroenterology Learning Network or HMP Global, their employees, and affiliates.
Joint and skin complications remain frequent among IBD patients even after escalation to advanced therapy, underscoring the importance of ongoing surveillance for EIMs.
Joint and skin complications remain frequent among IBD patients even after escalation to advanced therapy, underscoring the importance of ongoing surveillance for EIMs.
Host Raymond Cross, MD, calls on Dr Shirley Mekelburg-Cohen to discuss the importance of self-care among patients with IBD, what self-care consists of, and how to help patients learn to partner with their clinicians in controlling their...
Host Raymond Cross, MD, calls on Dr Shirley Mekelburg-Cohen to discuss the importance of self-care among patients with IBD, what self-care consists of, and how to help patients learn to partner with their clinicians in controlling their...
Dr James Lewis from the University of Pennsylvania and host Dr Raymond Cross discuss the risk of colon cancer among patients with inflammatory bowel disease, the importance of appropriate surveillance, and special considerations for choosing...
Dr James Lewis from the University of Pennsylvania and host Dr Raymond Cross discuss the risk of colon cancer among patients with inflammatory bowel disease, the importance of appropriate surveillance, and special considerations for choosing...
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Host Raymond Cross, MD, calls on Dr Shirley Mekelburg-Cohen to discuss the importance of self-care among patients with IBD, what self-care consists of, and how to help patients learn to partner with their clinicians in controlling their...
Host Raymond Cross, MD, calls on Dr Shirley Mekelburg-Cohen to discuss the importance of self-care among patients with IBD, what self-care consists of, and how to help patients learn to partner with their clinicians in controlling their...
Dr James Lewis from the University of Pennsylvania and host Dr Raymond Cross discuss the risk of colon cancer among patients with inflammatory bowel disease, the importance of appropriate surveillance, and special considerations for choosing...
Dr James Lewis from the University of Pennsylvania and host Dr Raymond Cross discuss the risk of colon cancer among patients with inflammatory bowel disease, the importance of appropriate surveillance, and special considerations for choosing...
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Clinical psychologist Megan Riehl, Psy D, talks with IBD Drive Time host Raymond Cross, MD, about the prevalence of anxiety and depression and even post-traumatic stress disorder among patients with inflammatory bowel disease--and how...
Clinical psychologist Megan Riehl, Psy D, talks with IBD Drive Time host Raymond Cross, MD, about the prevalence of anxiety and depression and even post-traumatic stress disorder among patients with inflammatory bowel disease--and how...
Host Raymond Cross, MD, welcomes back Dr Florian Rieder, an internationally recognized expert in penetrating and stricturing complications of Crohn's disease, to talk about diagnosing, performing endoscopy, and treating this challenging...
Host Raymond Cross, MD, welcomes back Dr Florian Rieder, an internationally recognized expert in penetrating and stricturing complications of Crohn's disease, to talk about diagnosing, performing endoscopy, and treating this challenging...
Host Raymond Cross, MD, and guest Dr Jason Schairer discuss the varieties of extraintestinal manifestations that may be seen in patients with IBD, how to diagnose them and when to rely on colleagues in dermatology, ophthalmology, and...
Host Raymond Cross, MD, and guest Dr Jason Schairer discuss the varieties of extraintestinal manifestations that may be seen in patients with IBD, how to diagnose them and when to rely on colleagues in dermatology, ophthalmology, and...
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...